Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors

Documenti analoghi

• Translational Model‐Informed Dose Selection for Iruplinalkib, a Selective Oral ALK / ROS1 Tyrosine Kinase Inhibitor
  di: Guihong Yang, et al.
  Pubblicazione: (2025)
• Correction to “Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers”
  Pubblicazione: (2024)
• Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod
  di: Qiudi Jiang, et al.
  Pubblicazione: (2024)
• Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist
  di: Yun Liu, et al.
  Pubblicazione: (2024)
• A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers
  di: Marie‐José Cabanis, et al.
  Pubblicazione: (2024)